An experiment was conducted to determine the effects of prebiotic on growth performance and coccidiosis prevention in challenged broilers with Eimeria. A total of 420 1-d-old male Ross 308 chicks were used in a completely randomized design with 7 treatments and 5 replicates with 12 birds in each replication. Dietary treatments were: 1) negative control (without prebiotic and without challenge), 2) positive control (challenged with sporulated oocysts of Eimeria (SOE) without prebiotic), 3) 0.2 % prebiotic in starter, 0.1 % in grower and 0.05 % in finisher challenged with SOE, 4) 0.2 % prebiotic in starter,0.1 % in grower and 0.05 % in finisher without challenge, 5) 0.2 % prebiotic in the whole rearing period challenged with SOE, 6) 0.2 % prebiotic in the whole rearing period without challenge and 7) and Salinomycin (0.05 % of diet). At 7 d of age, treatments were challenged with 20-fold dose of the EIMERIAVAX 4 m as a trivalent live attenuated coccidiosis vaccine. On d 28, intestinal coccidiosis lesions and dropping were scored in the scale of 0-3 and 0-4, respectively, and oocysts per gram feces (OPG) were measured. Prebiotic at either supplementation rate increased body weight gain and improved feed conversion ratio compared with PC group. Challenged broilers fed fixed level of prebiotic displayed lower OPG, dropping scores and coccidiosis lesions scores in upper and middle regions of intestine than PC group, with the effect being similar to unchallenged birds.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rvsc.2024.105440 | DOI Listing |
J Clin Med
December 2024
Health, Nutrition & Care, DSM-Firmenich, 4303 Kaiseraugst, Switzerland.
Biotics are increasingly being used in the treatment of irritable bowel syndrome (IBS). This study aimed to assess the efficacy and safety of a mixture of microencapsulated sodium butyrate, probiotics ( DSM 26357, DSM 32418, DSM 32946, DSM 32403, and DSM 32269), and short-chain fructooligosaccharides (scFOSs) in IBS patients. This was a randomized, double-blind, placebo-controlled trial involving 120 adult participants with IBS.
View Article and Find Full Text PDFCancers (Basel)
December 2024
Division of Hematology and Oncology, School of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, USA.
Dysbiosis in the gut microbiota plays a significant role in GI cancer development by influencing immune function and disrupting metabolic functions. Dysbiosis can drive carcinogenesis through pathways like immune dysregulation and the release of carcinogenic metabolites, and altered metabolism, genetic instability, and pro-inflammatory signalling, contributing to GI cancer initiation and progression. infection and genotoxins released from dysbiosis, lifestyle and dietary habits are other factors that contribute to GI cancer development.
View Article and Find Full Text PDFNutrients
December 2024
Cryptobiotix, Technologiepark-Zwijnaarde 82, 9052 Gent, Belgium.
Background: The human gut microbiota develops in concordance with its host over a lifetime, resulting in age-related shifts in community structure and metabolic function. Little is known about whether these changes impact the community's response to microbiome-targeted therapeutics. Providing critical information on this subject, faecal microbiomes of subjects from six age groups, spanning from infancy to 70-year-old adults (n = six per age group) were harvested.
View Article and Find Full Text PDFNutrients
December 2024
Pediatric Department, Buzzi Children's Hospital, 20154 Milano, Italy.
Introduction Emerging evidence suggests an association between obesity and Functional Gastrointestinal Disorders (FGIDs). Childhood obesity and FGIDs share many common features, such as high prevalence in the pediatric population, risk factors related to diet and lifestyle, gut microbiota impairments, and psychological distress. This narrative review aims to summarize the main evidence regarding FGIDs in childhood obesity, with a specific focus on the role of diet and its impact on the microbiota.
View Article and Find Full Text PDFNutrients
December 2024
Department of Molecular Biology and Genetics, Çanakkale Onsekiz Mart University, Çanakkale 17100, Türkiye.
Human milk oligosaccharides (HMOs), the third most abundant solid component in human milk, vary significantly among women due to factors such as secretor status, race, geography, season, maternal nutrition and weight, gestational age, and delivery method. In recent studies, HMOs have been shown to have a variety of functional roles in the development of infants. Because HMOs are not digested by infants, they act as metabolic substrates for certain bacteria, helping to establish the infant's gut microbiota.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!